Anti-HIV-1/HIV-2 protease Purified Azide Free

The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patents.

Product Specifications

Certification

RUO

Reactivity

Human Immunodeficiency Virus

Immunogen

Bacterially expressed full-length HIV-1 protease

Target Antigen

HIV-1/HIV-2 protease

Clone

1696

Applications

WB, ELISA, FUNC

Concentration

1 mg/mL

Format

Purified Azide Free

Buffer

Phosphate buffered saline (PBS), pH 7.4

References & Citations

*O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23 (4) :764-72., URL: https://www.ncbi.nlm.nih.gov/pubmed/16423863?dopt=, *Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78 (3) :275-7. Epub 2008 Feb 20., URL: https://www.ncbi.nlm.nih.gov/pubmed/18329737?ordin, *Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8 (12) :2686-96., URL: https://www.ncbi.nlm.nih.gov/pubmed/10631984?dopt=

Other References

*Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46 (51) :14854-64., URL: https://www.ncbi.nlm.nih.gov/pubmed/18052235?ordin, *Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9 (1) :181, URL: https://www.ncbi.nlm.nih.gov/pubmed/18402661?ordin, *Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71 (4) :298-305., URL: https://www.ncbi.nlm.nih.gov/pubmed/18312292?ordin, *Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98 (11) :6062-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/11353856?ordin

Storage Conditions

Store at 2-8°C. Do not freeze.

Specificity

The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.

Applications Notes

Functional application: The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases. Western blotting: Recommended dilution: 0.5 μg/ml.